<DOC>
	<DOCNO>NCT01767285</DOCNO>
	<brief_summary>The investigator examine difference continuation rate etonogestrel contraceptive implant woman device place immediately delivery , leave hospital , woman device place routine 6-week postpartum visit . There 60 subject total , randomize 1:1 ratio , 30 group . All participant follow-up postpartum clinic 6 week delivery . They contact 3 , 6 , 12 month postpartum ask complete brief survey . The investigator hypothesize continuation rate Implanon high immediate postpartum placement arm delay placement arm .</brief_summary>
	<brief_title>Immediate v . Delayed Postpartum Etonogestrel Implant</brief_title>
	<detailed_description />
	<mesh_term>Etonogestrel</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<criteria>1 ) Age 1240 year 2 ) Must deliver Duke Hospital 3 ) Must work telephone number 4 ) No contraindication receive method contraception , include : know suspected pregnancy , active liver disease hepatic tumor , current past history thrombosis thromboembolic disorder , undiagnosed abnormal genital bleeding , know suspect breast cancer history breast cancer , hypersensitivity component device . 1 . Not meet inclusion criterion 2 . Use chronic medical therapy adverse interaction etonogestrel . Medications cause exclusion study include : 1 . Nonnucleoside reverse transcriptase inhibitor 2. ritonavirboosted protease inhibitor 3 . Certain anticonvulsant phenytoin , carbamazepine , barbiturate , primidone , topiramate , oxcarbazepine 4 . Rifampin 5 . St. John 's Wort</criteria>
	<gender>Female</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Etonogestrel Implant</keyword>
	<keyword>Implanon</keyword>
	<keyword>Nexplanon</keyword>
	<keyword>Long Acting Reversible Contraception</keyword>
</DOC>